Headlines about MEI Pharma (NASDAQ:MEIP) have been trending somewhat positive on Friday, according to AlphaOne Sentiment. AlphaOne, a division of Accern, identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. MEI Pharma earned a news impact score of 0.11 on AlphaOne’s scale. AlphaOne also assigned media coverage about the company an impact score of 79 out of 100, meaning that recent media coverage is likely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted AlphaOne’s rankings:
- MEI Pharma (MEIP), Helsinn Group Announce Upcoming Presentations at ASCO – StreetInsider.com (streetinsider.com)
- Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia (finance.yahoo.com)
- Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion (finance.yahoo.com)
- Williams %R Check on Shares of MEI Pharma Inc (MEIP) – SKV News (skvnews.com)
- MEI Pharma, Inc. (NasdaqCM:MEIP) Valuation at a Glance – Lenox Ledger (lenoxledger.com)
Separately, Zacks Investment Research upgraded shares of MEI Pharma from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research note on Friday, February 17th.
MEI Pharma (NASDAQ:MEIP) traded down 1.22% during mid-day trading on Friday, reaching $1.62. 136,083 shares of the company’s stock traded hands. MEI Pharma has a 12 month low of $1.23 and a 12 month high of $2.28. The stock has a market capitalization of $59.57 million, a PE ratio of 47.65 and a beta of 1.01. The firm’s 50-day moving average price is $1.59 and its 200 day moving average price is $1.58.
MEI Pharma (NASDAQ:MEIP) last released its quarterly earnings data on Thursday, May 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). The company had revenue of $4.51 million for the quarter, compared to analyst estimates of $5 million. Equities research analysts predict that MEI Pharma will post $0.02 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “MEI Pharma (MEIP) Receives Daily Media Impact Rating of 0.11” was published by Mideast Time and is the property of of Mideast Time. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.mideasttime.com/mei-pharma-meip-receives-daily-media-impact-rating-of-0-11/1708447.html.
MEI Pharma Company Profile
MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Receive News & Ratings for MEI Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.